Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Inks Purchasing Deal with Premier

NEW YORK (GenomeWeb) – NeoGenomics today announced a three-year national group purchasing agreement with Premier to provide the healthcare alliance's members with full access to NeoGenomics' menu of oncology testing services. 

The deal makes Ft.Myers, Florida-based NeoGenomics the first specialized oncology reference laboratory to be a preferred in-network lab option for all Premier member hospitals, cancer centers, pathology groups, and oncology physician providers, the company said. Premier is a healthcare group purchasing organization composed of about 3,600 hospitals and 12,000 other provider members. 

The agreement gives its members access to NeoGenomics' services such as the next-generation sequencing-based NeoType Cancer Profiles. The NeoType tumor-specific profiling menu was recently expanded to include profiles for head and neck tumors, pancreatic cancer, liver cancer, sarcoma, and cancers of unknown primary. A complete analysis of somatic mutations in BRCA1 and 2 are now also a part of breast, ovarian, and pancreatic cancer profiling. 

NeoGenomics' shares on the Nasdaq rose about 6 percent to $6.29 in morning trading today.